期刊文献+

IL-18基因转染膀胱癌细胞的建立及其抑瘤作用研究 被引量:3

Construction of bladder carcinoma cells transducted by IL-18 and study of its antitumor effect
下载PDF
导出
摘要 目的将IL-18基因转染膀胱癌细胞(T24),检测该细胞体内外的凋亡变化,探讨IL-18的抗肿瘤作用机制。方法用含IL-18的基因IL-18/PA317转染T24细胞,经G418筛选后获得IL-18/T24阳性克隆。采用RT-PCR鉴定转染细胞mRNA的表达;用ELISA法检测IL-23/MA-891细胞培养上清中IL-18的分泌;用MTT比色法检测细胞体外增殖能力;观察IL-18/T24细胞生长情况、移植瘤的生长情况;用流式细胞技术检测体外和体内的细胞凋亡率。结果成功将IL-18基因转染T24细胞获得高表达IL-18细胞IL-18/T24。转染IL-18基因不影响T24细胞的体外生长和细胞凋亡,但体内IL-18基因转染组肿瘤生长明显受到抑制,肿瘤组织细胞凋亡率增高(P<0.01)。结论转染IL-18基因后对膀胱癌细胞(IL-18/T24)的体外凋亡无影响,但在体内IL-18能够诱导细胞凋亡,产生抗明显肿瘤作用。 Objective To set up bladder carcinoma cells (T24) transducted by IL-18 , and study its antitumor effect and related mechanism. Methods Transducted 124 cell with the culture supematant of IL-18/PA317 cells and gained IL-18/T24 cells selected with G418. IL-18 mRNA expression in IL-18/T24 cells was detected with RT-PCR. The expression of IL-18 protein was detected by ELISA. The proliferation of T24, LXSN/T24 and IL-18/T24 cells were detected by MTT colorimetry in vitro. Observe the growth of transplanted tumor in nude mouse. Flow cytometry was used to analyze the cell apoptosis.Results IL-18/T24 cells expressing IL-18 stably was successfully set up. The proliferation rate of IL-18/T24 cells showed no difference with parental cells, and the cell apoptosis of IL-18/T24 cells was similar in vitro( P 〉 0.05). Compared with the control group, growth rate of tumor in mice model was inhibited and cell apoptosis rate was increased significantly ( P 〈 0.01) in IL-18 gene therapy group. Conclusion The cellular clone IL-18/T24 with high level expression of IL-18 was produced and IL-18 has no effect on cell apoptosis in vitro, while it played a role in antitumor immunity by inducing cell apoptosis in vivo.
出处 《河北医药》 CAS 2008年第7期929-931,共3页 Hebei Medical Journal
基金 河北省科技厅科技攻关课题(编号:062761326)
关键词 IL-18 基因转染 膀胱癌细胞 抗肿瘤 凋亡 IL-18 gene transfection bladder carcinoma cells antitumor apoptosis
  • 引文网络
  • 相关文献

参考文献7

  • 1Micallef MJ, Yoshida K, Kawai S, et al. In vivo antitumor efffects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immtmol Immunother, 1997, 43: 361-367.
  • 2Oshikawa K, Shi F, Rakhmilevich AL, et al. Synergistic inhibition of tumor growth in a murine mammary adenocarcinorna model by combinational gene therapy using IL-12, pro-IL-18, and IL-1 beta converting enzyme cDNA.Proc Natl Acad Sci USA, 1999, 96:13351-13356.
  • 3Osaki T, Hashimoto W, Gambotto A, et al. Potent antitmnor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18(IL-18).Gene Ther, 1999, 65:808-815.
  • 4Tamura T, Nishi T,Goto T, et al. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res, 2003, 23:1173-1179.
  • 5Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interfon-gamma production. Eur J Immunol, 1996, 26: 1647.
  • 6Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN- gamma-inducing factor, expressionin Escherichia coli, and studies on the biologic activities of the protein. J Immunol, 1996,156:4274-4277.
  • 7Cao R, Farnebo J, Kurimoto M, et al. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J, 1999,13 : 2195-2202.

同被引文献14

  • 1Hong-Yu Jia,Jie Du,Si-He Zhu,Ying-Ji Ma,Huan-Yong Chen,Bao-Shan Yang,Hua-Feng Cai the Departments of Infectious Diseases and Pharmacy First Clinical College, Harbin Medical University, Harbin 150001, China.The roles of serum IL-18, IL-10, TNF-α and sIL-2R in patients with chronic hepatitis C[J].Hepatobiliary & Pancreatic Diseases International,2002,1(3):378-382. 被引量:1
  • 2Ping-AnZhang,Jian-MinWu,YanLi,Xiang-ShengYang.Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population[J].World Journal of Gastroenterology,2005,11(11):1594-1598. 被引量:28
  • 3王兆亮,朱建善,刘强,许雁萍.细胞角蛋白20在51例膀胱尿路上皮癌中的表达[J].上海医学,2005,28(6):487-489. 被引量:1
  • 4Moll R,Schiller DL,Franke WW.Identification of protein IT of the intestinal cytoskeleton as a novel type Ⅰ cytokeratin with unusual properties and expression patterns.J Cell Biol,1990,111:567-580.
  • 5Moll R,Lowe A,Laufer J,et al.Cytokeratin 20 in human carcinomas:A new histodiagnostic marker detected by monoclonal antibodies.Am J Pathol,1992,140:427-447.
  • 6Klein A,Zemer R,Buchumensky V,et al.Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.Cancer,1998,82:349-354.
  • 7Rotem D,Cassel A,Lindenfeld N,et al.Urinary cytokeratin 20 as a marker for transitional cell carcinoma.Eur Urol,2000,37:601-604.
  • 8Richhars L,Michael JD.The natural history of bladder cancer.N Am Urol Clin,2000,27:1-14.
  • 9David SS,Gennaro AC,Julio RV,et al.Evaluation of NMP 22 in the detection of transitional cell carcinoma of the bladder.J Urol,1998,159:394-398.
  • 10Keesee K,Brigmann JV,Thill G,et al.Utilization of nuclear matrix proteins for cancer diagnosis.Crit Rev Eukaryot Gene Expr,1996,6:189-214.

引证文献3

二级引证文献6

;
使用帮助 返回顶部